On Friday, X4 Pharmaceuticals Inc (NASDAQ: XFOR) was 3.76% up from the session before settling in for the closing price of $0.50. A 52-week range for XFOR has been $0.47 – $1.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.00%. When this article was written, the company’s average yearly earnings per share was at 80.70%. With a float of $117.19 million, this company’s outstanding shares have now reached $167.43 million.
Let’s determine the extent of company efficiency that accounts for 93 employees. In terms of profitability, gross margin is 69.97%, operating margin of -3411.51%, and the pretax margin is 489.32%.
X4 Pharmaceuticals Inc (XFOR) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward X4 Pharmaceuticals Inc stocks. The insider ownership of X4 Pharmaceuticals Inc is 30.45%, while institutional ownership is 38.46%. The most recent insider transaction that took place on Oct 15 ’24, was worth 17,926. In this transaction President and CEO of this company sold 31,897 shares at a rate of $0.56, taking the stock ownership to the 1,025,816 shares. Before that another transaction happened on Oct 15 ’24, when Company’s Officer proposed sale 31,897 for $0.56, making the entire transaction worth $17,862.
X4 Pharmaceuticals Inc (XFOR) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.01 earnings per share (EPS) during the time that was better than consensus figure (set at -0.15) by 0.14. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 80.70% per share during the next fiscal year.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Trading Performance Indicators
You can see what X4 Pharmaceuticals Inc (XFOR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 162.03.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.09, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.46 in one year’s time.
Technical Analysis of X4 Pharmaceuticals Inc (XFOR)
Looking closely at X4 Pharmaceuticals Inc (NASDAQ: XFOR), its last 5-days average volume was 1.59 million, which is a drop from its year-to-date volume of 2.06 million. As of the previous 9 days, the stock’s Stochastic %D was 48.53%. Additionally, its Average True Range was 0.04.
During the past 100 days, X4 Pharmaceuticals Inc’s (XFOR) raw stochastic average was set at 7.13%, which indicates a significant decrease from 37.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.80% in the past 14 days, which was lower than the 97.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6141, while its 200-day Moving Average is $0.8635. However, in the short run, X4 Pharmaceuticals Inc’s stock first resistance to watch stands at $0.5388. Second resistance stands at $0.5586. The third major resistance level sits at $0.5775. If the price goes on to break the first support level at $0.5001, it is likely to go to the next support level at $0.4812. Now, if the price goes above the second support level, the third support stands at $0.4614.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Key Stats
There are 168,500K outstanding shares of the company, which has a market capitalization of 90.74 million. As of now, sales total 0 K while income totals -101,170 K. Its latest quarter income was 560 K while its last quarter net income were 90,830 K.
